Compare PTRN & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTRN | GRDN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | 3400 |
| Industry | Catalog/Specialty Distribution | Retail-Drug Stores and Proprietary Stores |
| Sector | Consumer Discretionary | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | N/A | N/A |
| Metric | PTRN | GRDN |
|---|---|---|
| Price | $11.50 | $34.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $19.89 | ★ $33.33 |
| AVG Volume (30 Days) | ★ 834.7K | 150.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.63 | $19.50 |
| Revenue Next Year | $24.32 | N/A |
| P/E Ratio | ★ N/A | $117.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.19 | $17.78 |
| 52 Week High | $20.10 | $37.43 |
| Indicator | PTRN | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 64.22 |
| Support Level | $11.21 | $27.04 |
| Resistance Level | $15.09 | $34.98 |
| Average True Range (ATR) | 0.75 | 1.25 |
| MACD | 0.16 | 0.05 |
| Stochastic Oscillator | 88.17 | 94.44 |
Pattern Group Inc is an ecommerce accelerator, uses its technology platform, data science and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics and customer service. Brand partners that contract with the Company operate in various industries including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors and consumer electronics.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.